tbuckley/cabot-search huggingface dataset:
Clinico-Epidemiological Study of Epithelial Ovarian Cancer Mansoura Experience
Authors: Soumaya Mohamed Eteba, Maiy Abdul-Raheim Alshahat, Fatma Mohamed Farouk Akl, Nehal Kadry Mohammed
Journal: Cancer Research (2018)

Background & objective: Ovarian cancer is the fifth most common cancer affecting women today. The aim of this retrospective study was to present the epidemiological, pathological, clinical characteristics of epithelial ovarian cancer patients treated at Clinical Oncology and Nuclear Medicine Department, Mansoura University Hospitals in the period between January 2009 and December 2013, with evaluation of progression free survival (PFS) overall survival (OS) and prognostic factors. Patients & methods: This is a retrospective study of epithelial ovarian carcinoma women treated at Clinical Oncology and Nuclear Medicine Department, Mansoura University Hospitals (in the period between January 2009 and December 2013). Data were analyzed after being collected from the patients' medical records. Clinical abstract sheets for all cases were designed. Results: The median age was 55 years (19 – 80 years), 58 patients (39.2%) were ECOG performance status (PS) 1, whereas, 50 patients (33.8%) were PS 0 at presentation. Ninety five patients (64.2%) were postmenopausal at presentation, serous cystadenocarcinoma was the predominant histopathologic type found in 94 patients (63.5%), followed by Endometrioid type (17.5%), 79 patients (53.4%) had stage III disease and 33 patients (22.3%) had stage IV disease. The majority of patients (99 patients 66.9%) had grade III tumors, 140 patients (94.6%) in the study underwent surgical treatment, optimal debulking was done in 85 patients (60.7%), while, suboptimal debulking was done in 55 patients (39.3%), the median overall survival was 49 months, while the median progression free survival was 18 months. Conclusion: the median age was 55 years old, serous carcinoma was the predominant histopathological type. Stage III and IV predominated. Most patients underwent initially surgery followed by adjuvant chemotherapy. The median overall survival & PFS were 49 & 18 months, respectively. Age, tumor histopathology, stage, grade and tumor residue after debulking surgery were significant independent prognostic factors for epithelial ovarian cancer.
Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL
Authors: Marco Picardi, Roberta Della Pepa, Claudia Giordano, Irene Zacheo, Novella Pugliese, Chiara Mortaruolo, Fabio Trastulli, Antonio Giordano, Mariano Lucignano, Maria Di Perna, Marta Raimondo, Claudia Salvatore, Fabrizio Pane
Journal: Blood (2018)
Balancing the efficacy and toxicity of anti-CD47 antibodies by direct screening in humanized mouse models
Authors: Y. Li, T. Gan, Y. Guo, Y. Shen, Y. Yang, J. Ni
Journal: Annals of Oncology (2018)

Background: CD47 is a transmembrane protein found on the surface of many cells in the body. Its expression is often up-regulated in many cancer cells. The receptor of CD47 was identified as SIRPa, which is expressed on phagocytic cells. Engagement of SIRPa by CD47 serves as "do not eat me" signal, thus inhibiting the phagocytic activity of macrophages. Cancer cells often hijack this pathway by boosting CD47 expression on their surface, in order to prevent innate cell-mediated phagocytosis. Molecules blocking the CD47-SIRPa interaction will unleash such inhibition and promote tumor destruction. Accordingly, anti-CD47 antibodies offer new hope to successful cancer treatment. Despite people are enthusiastic about CD47 as a potential target, the side effects associated with CD47 blockade have emerged as a major concern. For example, treatment with anti-CD47 antibody greatly reduced the number of circulating red blood cells and platelets that also express CD47. Thus, the class of CD47 antibodies that stimulate tumor cell killing while sparing normal cells in vivo is desirable for the cancer patients. Methods: We are interested in understanding whether humanized mouse models could aid the evaluation of a variety of monoclonal CD47 antibodies we generated. We first screened them using the CDX platform established at Biocytogen. Indeed, most antibodies were able to clear human tumor cells in B-NDG mice. Then we screened the toxicity of these antibodies using humanized knocked-in mice. Body weight and blood were collected and analyzed. Results: Most antibodies were able to clear human tumor cells in B-NDG mice. However, when we screened the toxicity of these antibodies using humanized knocked-in mice, many antibodies caused rapid death of animals upon the first administration. Interestingly, we found two clonal antibodies bearing the least toxicity since the treated animals exhibited minimal weight loss on Day 2 and then recovered. Conclusions: We concluded that humanized mice could expedite the development of safer CD47 antibodies that can be advanced to human clinical trials. Legal entity responsible for the study: Chaoshe Guo. Funding: Beijing Biocytogen Co., Ltd. Disclosure: All authors have declared no conflicts of interest.
Alkylating agent exposure and sperm concentration in adult survivors of childhood cancer: A report from the St. Jude Lifetime (SJLIFE) Cohort Study.
Authors: Daniel M. Green, Wei Liu, William H. Kutteh, Raymond W. Ke, Kyla C. Shelton, Charles A. Sklar, Wassim Chemaitilly, Ching-Hon Pui, James Klosky, Sheri L. Spunt, Monika Metzger, Fariba Navid, Deo Kumar Srivastava, Kirsten K. Ness, Leslie L. Robison, Melissa M. Hudson
Journal: Journal of Clinical Oncology (2014)

10010 Background: Male survivors of childhood cancer treated with alkylating agents (AA) are at risk for azoospermia; however, the long-term dose-risk relationship is unknown. Methods: Of the 287 SJLIFE participants treated with AA but no radiation therapy, 214 provided an evaluable semen sample (mean age at diagnosis: 7.9 years, mean age at evaluation: 29.8 years, and mean years from diagnosis to evaluation: 21.6 years). Survivors were categorized as azoospermia, oligospermia (sperm concentration > 0 and < 15 million/ml), or normospermia (sperm concentration ≥ 15 million/ml). AA exposure was estimated using the cyclophosphamide equivalent dose (CED). Risks were estimated using the odds ratio (OR) and 95% confidence intervals (CI) from multinomial logistic regression analyses. Results: Among survivors 24.8% had azoospermia, 27.6% oligospermia, and 47.6% normospermia (Table). CED was negatively correlated with sperm concentration (r = - 0.25, p< 0.001). Neither age at diagnosis nor age at evaluation was significantly associated with increased risk for azoospermia. Treatment with cis-platinum or carboplatinum did not increase the risk of azoospermia or oligospermia. Adjusting for age at diagnosis and at follow-up, CED was statistically significantly associated with azoospermia (OR= 1.22, 95% CI 1.11, 1.34) and oligospermia (OR=1.14, 95% CI, 1.04, 1.25) for each 1000 mg/m2increase of CED. Conclusions: We identified neither a threshold dose, below which impaired spermatogenesis was unlikely, nor a dose above which azoospermia was uniformly present. This result suggests that other factors, including genetic variation in drug metabolizing pathways, may modulate the impact of AA exposure on spermatogenesis. Outcome No. CED (mg/m2) Mean SD Range Median Interquartile range Azoospermia 53 10,830 7,274 1,000 - 41,311 9,234 6,354-10,916 Oligospermia 59 8,480 4,264 2,100 - 31,894 8,000 5,650-9,872 Normospermia 102 6,626 3,576 1,016 - 15,645 6,137 3,386-9,396
Cardiovascular Health and Cognitive Decline
Authors: Robert H. Howland
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Significant Increase in Risk of Fibrosis or Cirrhosis at Time of HCV Diagnosis for Hispanics With Diabetes and Obesity Compared With Other Ethnic Groups
Authors: Barbara J. Turner, Chen-Pin Wang, Trisha V. Melhado, Raudel Bobadilla, Mamta K. Jain, Amit G. Singal
Journal: Clinical Gastroenterology and Hepatology (2018)
Mitochondrial Membrane Potential Regulates Nuclear Gene Expression in Macrophages Exposed to Prostaglandin E2
Authors: David E. Sanin, Mai Matsushita, Ramon I. Klein Geltink, Katarzyna M. Grzes, Nikki van Teijlingen Bakker, Mauro Corrado, Agnieszka M. Kabat, Michael D. Buck, Jing Qiu, Simon J. Lawless, Alanna M. Cameron, Matteo Villa, Francesc Baixauli, Annette E. Patterson, Fabian Hässler, Jonathan D. Curtis, Christina M. O’Neill, David O’Sullivan, Duojiao Wu, Gerhard Mittler, Stanley Ching-Cheng Huang, Erika L. Pearce, Edward J. Pearce
Journal: Immunity (2018)
Combined deficiency of SLAMF8 and SLAMF9 prevents endotoxin-induced liver inflammation by downregulating TLR4 expression on macrophages
Authors: Xiaokang Zeng, Guangao Liu, Wanwen Peng, Junming He, Chenxu Cai, Wei Xiong, Shasha Chen, Meixiang Yang, Zhongjun Dong
Journal: Cellular and Molecular Immunology (2018)
Impact of Modified Dose Schedule of Bortezomib, Melphalan, and Prednisone (VMP) for Previously Untreated, Transplant-Ineligible Patients with Multiple Myeloma (MM): A Matching-Adjusted Indirect Comparison
Authors: Jesus F San-Miguel, Maria-Victoria Mateos, Hartmut Goldschmidt, Pieter Sonneveld, Meletios A Dimopoulos, Bart Heeg, Mahmoud Hashim, William Deraedt, Peter Hu, Annette Lam, Jianming He
Journal: Blood (2018)
Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review
Authors: Seok Jin Kim, Sang Eun Yoon, Won Seog Kim
Journal: Journal of Hematology & Oncology (2018)

Extranodal natural killer/T cell lymphoma (ENKTL), nasal type, presents predominantly as a localized disease involving the nasal cavity and adjacent sites, and the treatment of localized nasal ENKTL is a major issue. However, given its rarity, there is no standard therapy based on randomized controlled trials and therefore a lack of consensus on the treatment of localized nasal ENKTL. Currently recommended treatments are based mainly on the results of phase II studies and retrospective analyses. Because the previous outcomes of anthracycline-containing chemotherapy were poor, non-anthracycline-based chemotherapy regimens, including etoposide and l-asparaginase, have been used mainly for patients with localized nasal ENKTL. Radiotherapy also has been used as a main component of treatment because it can produce a rapid response. Accordingly, the combined approach of non-anthracycline-based chemotherapy with radiotherapy is currently recommended as a first-line treatment for localized nasal ENKTL. This review summarizes the different approaches for the use of non-anthracycline-based chemotherapy with radiotherapy including concurrent, sequential, and sandwich chemoradiotherapy, which have been proposed as a first-line treatment for newly diagnosed patients with localized nasal ENKTL.
Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
Authors: Xi-Yu Liu, Ding Ma, Xiao-En Xu, Xi Jin, Ke-Da Yu, Yi-Zhou Jiang, Zhi-Ming Shao
Journal: Theranostics (2018)

Estrogen receptor-positive, progesterone receptor-negative, and human epidermal growth factor receptor 2 (HER2)-negative (ER+PR-HER2-) breast cancer comprise a special type of breast cancer that constitutes ~10% of all breast cancer patients.ER+PR-HER2-tumor benefits less from endocrine therapy, while its genomic features remain elusive.In this study, we systematically assessed the multiomic landscape and endocrine responsiveness of ER+PR-HER2-breast cancer.Methods: This study incorporated five cohorts.The first and second cohorts were from the Surveillance, Epidemiology, and End Results database (n=130,856) and Molecular Taxonomy of Breast Cancer International Consortium (n=1,055) for analyzing survival outcomes and endocrine responsiveness.The third cohort was from The Cancer Genome Atlas (n=630) for multiomic analysis and endocrine-resistant subgroup exploration.The fourth cohort, from the MD Anderson database (n=92), was employed to assist gene selection.The fifth cohort was a prospective observational cohort from Fudan University Shanghai Cancer Center (n=245) that was utilized to validate the gene-defined subgroup by immunohistochemistry (IHC).Results: Clinically, ER+PR-HER2-tumors showed lower endocrine responsiveness than did ER+PR+HER2-tumors.Genomically, copy number loss or promoter methylation of PR genes occurred in 75% of ER+PR-HER2-tumors, collectively explaining PR loss.ER+PR-HER2-tumors had higher TP53 (30.3% vs. 17.0%) and lower PIK3CA mutation rates (25.8% vs. 42.7%)and exhibited more ZNF703 (21.5% vs. 13.6%) and RPS6KB1 (18.5% vs. 7.8%) amplification events than ER+PR+HER2-tumors.Among ER+PR-HER2-tumors, nearly 20% were of the PAM50-defined non-luminal-like subgroup and manifested lower endocrine sensitivity scores and enriched biosynthesis, metabolism and DNA replication pathways.We further identified the non-luminal-like subgroup using three IHC markers, GATA3, CK5, and EGFR.These IHC-defined non-luminal-like (GATA3-negative, CK5-positive and/or EGFR-positive) tumors received limited benefit from adjuvant endocrine therapy.Conclusion: ER+PR-HER2-breast cancer consists of clinically and genomically distinct groups that may require different treatment strategies.The non-luminal-like subgroup was associated with reduced benefit from endocrine therapy.
Acute Mental Health Symptoms in Adolescent Marijuana Users
Authors: Sharon Levy, Elissa R. Weitzman
Journal: JAMA Pediatrics (2018)

Acute Mental Health Symptoms in Adolescent Marijuana UsersMarijuana use is associated with acute psychotic symptoms, 1 but the prevalence of these symptoms in youth is not known, to our knowledge.We surveyed adolescents presenting for routine medical care to assess whether they had experienced acute psychotic symptoms during or right after marijuana use.
Abstract 21021: Functional Regulatory Mechanism of Smooth Muscle Cell-Restricted <i>LMOD1</i> Coronary Artery Disease Locus
Authors: Vivek Nanda, Ting Wang, Dharini Iyer, Milos Pjanic, Boxiang Liu, Trieu Nguyen, Joseph M Miano, Thomas Quertermous, Nicholas J Leeper, Clint L Miller
Journal: Circulation (2017)

Coronary artery disease (CAD) remains the leading cause of mortality and morbidity worldwide and has an estimated heritability of 40%. Meta-analyses of genome-wide association studies have now identified 73 genome-wide significant loci and the most recent multi-ethnic meta-analysis identified a number of arterial wall-specific loci. One of these loci include the smooth muscle cell-restricted factor, LMOD1 (Leiomodin 1), a member of the actin filament nucleator family that is highly enriched in smooth muscle tissues including main arteries and visceral organs of the gastrointestinal system. We hypothesized that LMOD1 may serve as a potent marker of the phenotypic modulation of smooth muscle cells during atherosclerosis. We recently identified a non-coding regulatory variant, rs34091558, which is in linkage disequilibrium with the lead CAD GWAS variant, rs2820315 (P=7.7E-10; OR=1.05). However, the causal mechanism for how these variants alter LMOD1 expression/function and CAD risk remains unclear. Expression quantitative trait loci (eQTL) mapping in GTEx and STARNET databases confirmed that rs34091558 is among the top eQTLs for LMOD1 in vascular tissues. Allelic expression imbalance analyses in heterozygous HCASMC donors further demonstrated cis-acting effects on LMOD1 gene expression. Position weight matrix (PWM) motif analyses identified the protective allele at rs34091558 to form a consensus forkhead box O3 (FOXO3) binding motif, which is predicted to be disrupted by the risk allele. FOXO3 chromatin immunoprecipitation and reporter assays demonstrated reduced FOXO3 binding and transcriptional activity by the risk allele in HCASMC. Platelet-derived growth factor BB (PDGF-BB) stimulation also significantly reduced LMOD1 expression coincident with FOXO3 knockdown. Finally, both gain and loss-of-function for FOXO3 and LMOD1 in HCASMC delineated a regulatory circuit by which LMOD1 decreased HCASMC proliferation and migration and increased cell contraction. Taken together, these results provide compelling functional evidence that: 1) common genetic variation is associated with dysregulation of LMOD1 expression, and 2) changes in vessel wall processes through LMOD1 dysregulation may partially explain the heritable risk for CAD.
Abstract MP037: Blood Pressure Genetic Risk Score Predicts Blood Pressure Responses to Dietary Sodium and Potassium Interventions: The GenSalt Study
Authors: Jovia Nierenberg, Changwei Li, Jiang He, Dongfeng Gu, James E Hixon, Dabeeru C Rao, Tanika N Kelly
Journal: Circulation (2017)

Salt-sensitivity of blood pressure (BP) is a risk factor for hypertension, cardiovascular disease and all-cause mortality. Although documented as an important BP endophenotype, the relationship between genetic loci implicated in BP and BP salt-sensitivity remains unexamined. We assessed the hypothesis that weighted genetic risk scores (GRS), based on SNPs identified in previous BP genome-wide association study meta-analyses, would predict BP salt-sensitivity among participants of the Genetic Epidemiology Network of Salt-Sensitivity (GenSalt) study. The GenSalt study was conducted among 1,906 participants from 633 Han Chinese families. Participants underwent a 7-day low sodium (51.3 mmol sodium/day), 7-day high sodium (307.8 mmol sodium/day), and 7-day high sodium plus potassium (60 mmol potassium/day) feeding study. BP was measured nine times at baseline and at the end of each intervention period using a random-zero sphygmomanometer. The relationships between systolic BP (SBP), diastolic BP (DBP) and mean arterial pressure (MAP) GRS and respective SBP, DBP and MAP responses to the dietary interventions were assessed using mixed linear regression models that accounted for familial dependencies and adjusted for age, gender, field center, and baseline body mass index and BP. As expected, baseline SBP, DBP, and MAP significantly increased per quartile increase in GRS(p=5.6 х 10 -11 , p=1.3 х 10 -7 , and p=9.9 х 10 -5 ). In contrast, increasing GRS quartile conferred smaller SBP, DBP, and MAP responses to the low sodium intervention (p=4.2 х 10 -3 , p=0.02, and p=7.3 х 10 -3 , respectively) and smaller SBP responses to the high sodium and potassium interventions (p=0.05 and p=0.03, respectively) ( Figure ). Similar results were obtained when the data were analyzed per standard deviation increase in GRS. In summary, we identified an inverse relationship between BP GRS and BP salt-sensitivity. Further studies will be needed to elucidate the biological mechanisms contributing to this novel finding.
In minor head trauma, decision rules were sensitive for intracranial findings, but reductions in CT use varied
Authors: Taylor Oliver, Heather Murray
Journal: Annals of Internal Medicine (2018)

Source Citation Foks KA, van den Brand CL, Lingsma HF, et al. External validation of computed tomography decision rules for minor head injury: prospective, multicentre cohort study in the Netherlands. BMJ. 2018;362:k3527. 30143521
Abstract 16626: Empagliflozin Improves Cardiovascular (CV) Outcomes Regardless of Improvement in Cardiac and Vascular Hemodynamic Markers in Type 2 Diabetes Patients at High CV Risk in EMPA-REG OUTCOME
Authors: Robert J Chilton, Lars Gullestad, Sung-Ha Park, David Fitchett, Silvio E, Uwe Hehnke, Hans Juergen Woerle, Odd Erik Johansen
Journal: Circulation (2017)

Introduction: In EMPA-REG OUTCOME, empagliflozin (empa) significantly reduced CV death by 38% (HR 0.62; 95% CI: 0.49, 0.77) and hospitalization for heart failure and HF death by 39% (0.61 (0.47, 0....
British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018
Authors: D. Gilson, S.J. Whittaker, F.J. Child, J.J. Scarisbrick, T.M. Illidge, E.J. Parry, M.F. Mohd Mustapa, L.S. Exton, E. Kanfer, K. Rezvani, C.E. Dearden, S.L. Morris, P.M. McHenry, T.A. Leslie, S. Wakelin, R.Y.P. Hunasehally, M. Cork, G.A. Johnston, N. Chiang, F.S. Worsnop, A. Salim, D. Buckley, G. Petrof, N. Callachand, T. Flavell, A.A. Salad
Journal: British Journal of Dermatology (2018)

Linked Editorial:Wang and Bagot. Br J Dermatol 2019; 180:443–444.
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis
Authors: Margreet Kloppenburg, Charles Peterfy, Ida K Haugen, Féline Kroon, Su Chen, Li Wang, Wei Liu, Gwen Levy, Roy M Fleischmann, Francis Berenbaum, Désirée van der Heijde, Prashant Bansal, Ruth Wittoek, Sheng Feng, Yuni Fang, Mary Saltarelli, Jeroen K Medema, Marc C Levesque
Journal: Annals of the Rheumatic Diseases (2018)

Objective To assess the efficacy, safety, pharmacokinetics and pharmacodynamics of the anti-interleukin (IL)-1α/β dual variable domain immunoglobulin lutikizumab (ABT-981) in erosive hand osteoarthritis (HOA). Methods Patients with ≥1 erosive and ≥3 tender and/or swollen hand joints were randomised to placebo or lutikizumab 200 mg subcutaneously every 2 weeks for 24 weeks. The primary endpoint was change in Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain subdomain score from baseline to 16 weeks. At baseline and week 26, subjects had bilateral hand radiographs and MRI of the hand with the greatest number of baseline tender and/or swollen joints. Continuous endpoints were assessed using analysis of covariance models, with treatment and country as main factors and baseline measurements as covariates. Results Of 132 randomised subjects, 1 received no study drug and 110 completed the study (placebo, 61/67 (91%); lutikizumab, 49/64 (77%)). AUSCAN pain was not different among subjects treated with lutikizumab versus placebo at week 16 (least squares mean difference, 1.5 (95% CI –1.9 to 5.0)). Other clinical and imaging endpoints were not different between lutikizumab and placebo. Lutikizumab significantly decreased serum high-sensitivity C reactive protein levels, IL-1α and IL-1β levels, and blood neutrophils. Lutikizumab pharmacokinetics were consistent with phase I studies and not affected by antidrug antibodies. Injection site reactions and neutropaenia were more common in the lutikizumab group; discontinuations because of adverse events occurred more frequently with lutikizumab (4/64) versus placebo (1/67). Conclusion Despite adequate blockade of IL-1, lutikizumab did not improve pain or imaging outcomes in erosive HOA compared with placebo.
Left ventricular reverse remodelling predicts long‐term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry
Authors: Marianna Adamo, Cosmo Godino, Cristina Giannini, Andrea Scotti, Riccardo Liga, Salvatore Curello, Claudia Fiorina, Ermanna Chiari, Giuliano Chizzola, Alessandro Abbenante, Emanuele Visco, Luca Branca, Francesca Fiorelli, Eustachio Agricola, Stefano Stella, Carlo Lombardi, Antonio Colombo, Anna Sonia Petronio, Marco Metra, Federica Ettori
Journal: European Journal of Heart Failure (2018)